Dr. Avtar Dhillon Leads Arch Therapeutics (ARTH) After Successful Positions With ONCS and INO
15 Juli 2013 - 2:30PM
Marketwired
The following is and investment opinion on Inovio Pharmaceuticals
(NYSE MKT: INO), Arch Therapeutics (OTCQB: ARTH), Merck (NYSE: MRK)
and OncoSec medical (OTCQB: ONCS).
Dr. Avtar Dhillon has been announced as the Chairman of the
Board of Directors for Arch Therapeutics (OTCQB: ARTH) after
leading Inovio Pharmaceuticals (NYSE MKT: INO) as CEO for over 7
years. Previously, Dr. Dhillon was the President and Chief
Executive Officer of Inovio Pharmaceuticals, Inc. (formerly Inovio
Biomedical Corporation) from October 2001 to June 2009. Under his
reign, Inovio enjoyed tremendous success corporately and publicly
where in 2004, Inovio Pharmeceuticals reached over $7.50 per
share.
Dr. Dhillon has a multi-faceted background in the medical field,
as both an executive on the board of different healthcare companies
as well as being involved with one of North America's leading
healthcare venture capital firms, MDS Capital, now Lumira Capital
Corp.
Dr. Dhillon helped lead the turnaround of Inovio through
restructuring, the acquisition of technology and a merger with VGX
Pharmaceuticals to help develop a vertically integrated DNA vaccine
development company. He also spearheaded multiple financings and
closed several licensing deals with the likes of Wyeth (now Pfizer)
and Merck (NYSE: MRK). Dr. Avtar Dhillon is now helping to lead
Arch Therapeutics along the path to success.
Arch Therapeutics, Inc. (OTCQB: ARTH) is a medical device
company developing a novel approach to stop bleeding (hemostasis)
and control leaking (sealant) during surgery and trauma care.
Arch's flagship development stage product candidate known as AC5™
is being designed to elegantly achieve hemostasis in minimally
invasive and open surgical procedures. For more information about
Arch Therapeutics please visit www.archtherapeutics.com
Information, opinions and analysis contained herein are based on
sources believed to be reliable, but no representation, expressed
or implied, is made as to its accuracy, completeness or
correctness. The opinions contained herein reflect our current
judgment and are subject to change without notice. We accept no
liability for any losses arising from an investor's reliance on or
use of this report. This report is for information purposes only,
and is neither a solicitation to buy nor an offer to sell
securities. A third party has hired and paid IO Circuit twelve
hundred and ninety five dollars for the publication and circulation
of this news release. Certain information included herein is
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning manufacturing, marketing, growth, and
expansion. Such forward-looking information involves important
risks and uncertainties that could affect actual results and cause
them to differ materially from expectations expressed herein. We
have no ownership of equity, no representation; do no trading of
any kind and send no faxes or emails.
IO Circuit Email Contact
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere IO Circuit News-Artikel